臨床研究等提出・公開システム

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of Eptinezumab for the Preventive Treatment of Migraine

Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine (Sunrise)

Yazawa Masanari

Lundbeck Japan K.K.

Kamiyacho Prime Place, 4-1-17 Toranomon, Minato-ku, Tokyo

mnya@lundbeck.com

Narita Takanori

PPD-SNBL K.K.

Nakanoshima Daibiru 16F 3-3-23 nakanoshima, Kita-ku, Osaka

+81-80-8027-6361

Takanori.Narita@ppd.com

Not Recruiting

May. 31, 2021

Interventional

randomized controlled trial

double blind

placebo control

parallel assignment

treatment purpose

- The patient has a diagnosis of CM as defined by IHS ICHD-3 guidelines confirmed at screening visit with a history of migraine onset at least 12 months prior to the Screening Visit.
- The patient has had a diagnosis of migraine at <=50 years of age.
- The patient has >= 8 migraine days per month for each month within the past 3 months prior to the Screening Visit.
- The patient fulfils the following criteria for migraine in prospectively collected information in the eDiary during the screening period:
- Migraine occurring on >=8 days and headache occurring on >=15 to <=26 days.
- The patient has demonstrated compliance with the Headache eDiary by entry of data for at least 24 of the 28 days following the Screening Visit.
- The patient is aged >=18 (>=20 for Taiwan) and <=75 years at the Screening Visit.

- The patient has received any medication targeting the calcitonin generelated peptide (CGRP) pathway as preventive treatment of migraine.
- The patient has confounding and clinically significant pain syndromes, (for example, fibromyalgia, chronic low back pain, complex regional pain syndrome).
- The patient has a diagnosis of acute or active temporomandibular disorder.
- The patient has a history or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), ophthalmoplegic migraine, migraine with brainstem aura and migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration).
- The patient has a lifetime history of psychosis, bipolar mania, or dementia.
- Patients with other psychiatric conditions whose symptoms are not controlled or who have not been adequately treated for a minimum of 6 months prior to screening are also excluded.
- The patient has a history of clinically significant cardiovascular disease, including uncontrolled hypertension, vascular ischaemia or thromboembolic events (for example, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism).

Both

Migraine

Eptinezumab 100 mg, eptinezumab 300 mg or placebo administered intravenously

Change from baseline in the number of monthly migraine days (MMDs) (Weeks 1-12)
[Time Frame: Weeks 1-12]

+81-92-691-3881

Mar. 17, 2021

No

China/Republic of Korea/Spain/Taiwan/Georgia/Poland/Slovakia